GET DAILY SIGNALSLumexa Imaging (LMRI) Earnings Preview: What to Expect From Q3 2026 Results
Key Takeaways
- Lumexa Imaging is scheduled to report its third quarter 2026 results after the market close on Tuesday, November 10, 2026, followed by a conference call at 5:00 p.m. ET.
- Analyst consensus clusters around $0.20 in adjusted earnings per share (EPS) and roughly $269 million in revenue, a modest step up from the second quarter.
- Advanced imaging modalities — magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) — are the key margin driver, with PET volumes up 23.2% year over year in Q2.
- Full-year 2026 guidance calls for EPS of $0.71–$0.77 and revenue of $1.045–$1.09 billion, leaving the company little room to disappoint.
- Wall Street rates LMRI a Strong Buy with an average price target of $17.67, implying notable upside from recent trading levels.
- A pending Medicare (CMS) site-neutral payment rule for non-contrast imaging, effective January 2027, could accelerate volume migration toward outpatient centers like Lumexa's.
- For deeper context, explore Lumexa Imaging's Major News, Today's Price Move, Price Targets, and Forecast on Tickeron.
- Explore Trending AI Robots to see how AI-driven strategies are positioning across the market this earnings season.
Earnings Context and Why It Matters
Lumexa Imaging is one of the nation's largest providers of outpatient diagnostic imaging, operating more than 190 centers across 13 states. The company's story centers on shifting volume from costly hospital settings to lower-cost outpatient facilities, a trend amplified by recent Medicare payment policy. This report matters because it tests whether Lumexa can convert favorable structural tailwinds into consistent execution. After posting back-to-back EPS beats in the first half of 2026, the stock has rebounded sharply from its 52-week low. Investors are watching whether advanced-imaging volume growth — the segment that drives profitability — remains intact and whether the company stays on track for its full-year guidance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Heading into the release, Wall Street expects Lumexa to report adjusted EPS of approximately $0.20 on revenue near $269 million, representing sequential improvement over the $0.20 EPS and $264.2 million revenue reported in the second quarter of 2026. Full-year 2026 guidance, reaffirmed in August, projects EPS of $0.71–$0.77 and revenue of $1.045–$1.09 billion.
Key metrics to watch include advanced-modality mix, which reached a record 37.4% of total volume in Q2, and PET volume growth, which surged 23.2% year over year. Investors will also monitor adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margins, which compressed to 21.4% in Q2 from 22.4% a year earlier due partly to public-company costs, as well as free cash flow, which hit a record $23.1 million last quarter. Historically, LMRI has beaten consensus EPS in each of the last two quarters, and its shares have shown sensitivity to guidance updates and commentary on new joint-venture partnerships.
Market Reaction and Investor Sentiment
Sentiment into the print is broadly constructive but guarded. Lumexa's shares have climbed off their 52-week low of $6.45 and closed near $13.97 ahead of the report, reflecting renewed analyst enthusiasm — 10 analysts now rate the stock a Strong Buy with a mean target of $17.67. Recent initiations from Truist Securities and Raymond James underscore growing conviction in the outpatient imaging thesis. At the same time, investors remain skeptical about whether management can deliver a stronger second half after weather-related disruptions and higher costs weighed on early 2026. A modest downward drift in EPS estimates over the past 60 days signals some caution. The market will likely react most to advanced-imaging volume trends, margin trajectory, and any update to full-year guidance.
Forward Outlook and Key Factors to Monitor
The most important catalyst beyond this report is regulatory. The Centers for Medicare & Medicaid Services (CMS) has finalized a site-neutral payment rule for certain non-contrast imaging services, effective January 1, 2027. Analysts view this as a structural tailwind that could push hospitals toward joint-venture arrangements and redirect volume to independent outpatient centers — a dynamic that directly favors Lumexa's model.
Investors should also track the company's expansion pipeline. Lumexa has targeted opening eight to ten new "de novo" centers annually and has announced joint ventures with major health systems, including UPMC and Hospital for Special Surgery. The pace and quality of these partnerships will influence long-term growth and margin expansion.
Finally, watch cost and cash-flow trends. Adjusted EBITDA margins compressed slightly in Q2, reflecting the added expense of operating as a newly public company, while free cash flow reached a record. Whether Lumexa can sustain that cash generation while funding expansion will be central to the stock's next move. As always, guidance commentary on the call — rather than the headline numbers alone — will likely set the tone for shares in the days ahead.
My Experience With Tickeron AI Tools
In preparing for earnings like this one, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get a quick sense of how sentiment and technical patterns are shifting around the name. It helps me cross-check analyst views against real-time data without spending hours on manual review. The platform also lets me scan for similar setups in the healthcare sector, which adds useful context when weighing whether the upcoming print could move the stock meaningfully.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LMRI in upward trend: price rose above 50-day moving average on October 23, 2026
LMRI moved above its 50-day moving average on October 23, 2026 date and that indicates a change from a downward trend to an upward trend. In 4 of 4 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on LMRI as a result. In 11 of 13 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for LMRI just turned positive on October 06, 2026. Looking at past instances where LMRI's MACD turned positive, the stock continued to rise in 4 of 5 cases over the following month. The odds of a continued upward trend are 80%.
The 10-day moving average for LMRI crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +5.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where LMRI advanced for three days, in 38 of 46 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 15 of 19 cases where LMRI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LMRI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
LMRI broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.098) is normal, around the industry mean (4.142). P/E Ratio (-46.532) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.075) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. LMRI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LMRI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement